Moon C A, Vince M
Health Centre, Redruth, Cornwall.
Br J Clin Pract. 1996 Jul-Aug;50(5):240-4.
A six-week, double-blind, randomised study was used to compare the efficacy, tolerability, safety and effect on cognitive function of paroxetine with that of lofepramine in the treatment of 138 patients with major depression in general practice. Efficacy was assessed using the Montgomery and Asberg Depression Rating Scale (MADRS) and Clinical Global Impression (CGI) scale. Effect on cognitive function was assessed using the paired associate learning test and the serial "E' cancellation test. The results showed that the antidepressant efficacy of paroxetine was comparable to that of lofepramine in the treatment of depressed patients. Similar improvements in mean total MADRS scores were observed in both treatment groups, but a significantly greater improvement was seen in the CGI with paroxetine at weeks 2 and 4. The effect of treatment on cognitive function did not differ significantly across the two treatment groups, nor did the number of adverse events reported nor the overall tolerability.
一项为期六周的双盲随机研究，用于比较帕罗西汀和洛非普明在全科医疗中治疗138例重度抑郁症患者时的疗效、耐受性、安全性及对认知功能的影响。使用蒙哥马利和阿斯伯格抑郁评定量表（MADRS）及临床总体印象量表（CGI）评估疗效。使用配对联想学习测试和连续“E”划消测试评估对认知功能的影响。结果显示，在治疗抑郁症患者方面，帕罗西汀的抗抑郁疗效与洛非普明相当。两个治疗组的平均MADRS总分均有类似改善，但在第2周和第4周时，帕罗西汀在CGI量表上的改善更为显著。两个治疗组在治疗对认知功能的影响、报告的不良事件数量或总体耐受性方面均无显著差异。
